PMC:7534795 / 39680-40092 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T184","span":{"begin":51,"end":54},"obj":"Body_part"},{"id":"T185","span":{"begin":255,"end":260},"obj":"Body_part"},{"id":"T186","span":{"begin":284,"end":292},"obj":"Body_part"},{"id":"T187","span":{"begin":317,"end":322},"obj":"Body_part"}],"attributes":[{"id":"A184","pred":"fma_id","subj":"T184","obj":"http://purl.org/sig/ont/fma/fma24890"},{"id":"A185","pred":"fma_id","subj":"T185","obj":"http://purl.org/sig/ont/fma/fma67498"},{"id":"A186","pred":"fma_id","subj":"T186","obj":"http://purl.org/sig/ont/fma/fma85272"},{"id":"A187","pred":"fma_id","subj":"T187","obj":"http://purl.org/sig/ont/fma/fma68646"}],"text":"• TACTIC-E Trial\n• Immunomodulatory agents • Multi-arm randomized trial\n• Pre-intensive care unit (ICU) COVID-19 patients\n• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care\n• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days\n• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)"}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T66","span":{"begin":51,"end":54},"obj":"Body_part"},{"id":"T67","span":{"begin":255,"end":260},"obj":"Body_part"}],"attributes":[{"id":"A66","pred":"uberon_id","subj":"T66","obj":"http://purl.obolibrary.org/obo/UBERON_0001460"},{"id":"A67","pred":"uberon_id","subj":"T67","obj":"http://purl.obolibrary.org/obo/UBERON_0000062"}],"text":"• TACTIC-E Trial\n• Immunomodulatory agents • Multi-arm randomized trial\n• Pre-intensive care unit (ICU) COVID-19 patients\n• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care\n• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days\n• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)"}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T317","span":{"begin":104,"end":112},"obj":"Disease"}],"attributes":[{"id":"A317","pred":"mondo_id","subj":"T317","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"}],"text":"• TACTIC-E Trial\n• Immunomodulatory agents • Multi-arm randomized trial\n• Pre-intensive care unit (ICU) COVID-19 patients\n• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care\n• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days\n• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T263","span":{"begin":51,"end":54},"obj":"http://www.ebi.ac.uk/efo/EFO_0001410"},{"id":"T264","span":{"begin":255,"end":260},"obj":"http://purl.obolibrary.org/obo/UBERON_0003103"},{"id":"T265","span":{"begin":317,"end":322},"obj":"http://purl.obolibrary.org/obo/GO_0005623"}],"text":"• TACTIC-E Trial\n• Immunomodulatory agents • Multi-arm randomized trial\n• Pre-intensive care unit (ICU) COVID-19 patients\n• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care\n• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days\n• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T299","span":{"begin":141,"end":145},"obj":"Chemical"},{"id":"T300","span":{"begin":158,"end":171},"obj":"Chemical"},{"id":"T301","span":{"begin":174,"end":185},"obj":"Chemical"},{"id":"T302","span":{"begin":365,"end":376},"obj":"Chemical"}],"attributes":[{"id":"A299","pred":"chebi_id","subj":"T299","obj":"http://purl.obolibrary.org/obo/CHEBI_23888"},{"id":"A300","pred":"chebi_id","subj":"T300","obj":"http://purl.obolibrary.org/obo/CHEBI_85078"},{"id":"A301","pred":"chebi_id","subj":"T301","obj":"http://purl.obolibrary.org/obo/CHEBI_135949"},{"id":"A302","pred":"chebi_id","subj":"T302","obj":"http://purl.obolibrary.org/obo/CHEBI_135949"}],"text":"• TACTIC-E Trial\n• Immunomodulatory agents • Multi-arm randomized trial\n• Pre-intensive care unit (ICU) COVID-19 patients\n• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care\n• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days\n• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)"}

{"project":"LitCovid-sentences","denotations":[{"id":"T286","span":{"begin":0,"end":16},"obj":"Sentence"},{"id":"T287","span":{"begin":17,"end":71},"obj":"Sentence"},{"id":"T288","span":{"begin":72,"end":121},"obj":"Sentence"},{"id":"T289","span":{"begin":122,"end":203},"obj":"Sentence"},{"id":"T290","span":{"begin":204,"end":340},"obj":"Sentence"},{"id":"T291","span":{"begin":341,"end":412},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"• TACTIC-E Trial\n• Immunomodulatory agents • Multi-arm randomized trial\n• Pre-intensive care unit (ICU) COVID-19 patients\n• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care\n• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days\n• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)"}

{"project":"LitCovid-PubTator","denotations":[{"id":"1337","span":{"begin":104,"end":112},"obj":"Disease"}],"attributes":[{"id":"A1337","pred":"tao:has_database_id","subj":"1337","obj":"MESH:C000657245"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"• TACTIC-E Trial\n• Immunomodulatory agents • Multi-arm randomized trial\n• Pre-intensive care unit (ICU) COVID-19 patients\n• Immunomodulatory drug EDP1815 vs. dapagliflozin + ambrisentan vs. standard care\n• Primary outcome includes need for cardiovascular organ support • EDP1815 as 2 capsules twice daily (1.6 × 1011 cells) for up to 7 days\n• Dapagliflozin 10 mg + ambrisentan 5 mg once daily (NCT04393246, 2020)"}